Elisigen has successfully closed a Series C funding round of 42 billion KRW. With participation from prominent investors, including the K-Bio/Vaccine Fund No. 3, the company has secured significant capital to accelerate clinical programs and bolster its R&D capabilities.
Read Original Article (Korean)
*Note: This link will redirect you to the original source in Korean.